Chadwick Mills

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Lyell Immunopharma, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, on its $425 million initial public offering of 25,000,000 shares of its common stock. Partners Dave Peinsipp, Charlie Kim, Chad Mills and Lauren Creel led the Cooley team advising Lyell on its public debut, which marks the third largest biotech IPO in history.

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Cooley advised BioMarin Pharmaceutical on its $720 million follow-on offering.

BioMarin is a developer of biopharmaceuticals for diseases and medical assistance.